Biopharmaceutical company Sosei Group Corporation (TSE:4565) reported on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for APP13007 for the launch of a first-in-human (FIH) clinical trial in the US eye inflammation market.
This FDA approval was awarded to Formosa Pharmaceuticals Inc.
The milestone FDA approval has triggered a USD2.5m payment to Sosei Heptares from Formosa.
APP13007 was originally designed and developed at Activus Pharma Inc, formerly a wholly owned subsidiary of Sosei. Activus was divested in 2017 to Formosa, a wholly owned subsidiary of Formosa Laboratories Inc.
APP13007 is a nanoparticle formulation of the corticosteroid clobetasol in development for the treatment of post-operative inflammation of the eye.
Sosei Heptares received USD3.5m plus JPY5m in upfront cash on signing the agreement and is entitled to receive undisclosed milestone payments based on progression of Activus' pipeline as well as royalties from the commercialisation of certain products should they reach the market.
(USD1=JPY107.743)
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007